Content
07/23/2024
Boston, MA USA
Third Arc Bio
completed $165 million Series A Round funding. Investors include
Hillhouse Investment (lead), Cormorant Asset Management (lead), Vida Ventures (lead), Foresite Capital, T. Rowe Price, AbbVie Ventures, BVF Partners, Goldman Sachs, Omega Funds, Janus Henderson Investors, Logos Capital, Freepoint Capital Group.
About
Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. The company's drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging two technologies that power a pipeline of high value therapeutics - a solid tumor synergy platform and an I&I platform that offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety.
Startup
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
